Polymorphisms in CYP-mediated arachidonic acid routes affect the outcome of renal transplantation

European Journal of Clinical Investigation

Volumn 45, Issue 10, 2015, Pages 1060-1068

  Gervasini, Guillermo ^a   García Cerrada, Montserrat ^a   Vergara, Esther ^b   García Pino, Guadalupe ^b   Alvarado, Raul ^b   Fernández Cavada, Maria Jesús ^b   Barroso, Sergio ^b   Doblaré, Emilio ^b   Cubero, Juan José ^b  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b HOSPITAL INFANTA CRISTINA   (Spain)

Author keywords

Creatinine clearance; CYP450; Delayed graft function; Graft survival; Polymorphisms; Renal transplant

Indexed keywords

ARACHIDONIC ACID; CREATININE; CYTOCHROME P450; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2J2; CYTOCHROME P450 4A11; CYTOCHROME P450F2; ENZYME VARIANT; GENOMIC DNA; UNCLASSIFIED DRUG; ARACHIDONATE EPOXYGENASE;

ADULT; ALLELE; ARACHIDONIC ACID METABOLISM; ARTICLE; CAUCASIAN; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DELAYED GRAFT FUNCTION; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC ASSOCIATION; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; INCIDENCE; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; ALLOGRAFT; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HOMOZYGOTE; KIDNEY DISEASES; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ADULT; ALLOGRAFTS; ARACHIDONIC ACID; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENOTYPE; GRAFT SURVIVAL; HOMOZYGOTE; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES;

EID: 84941995303     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12507     Document Type: Article

References (40)

1. Imig JD. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol 2005;289:F496-503.
2. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999;285:1276-9.
3. Miyata N, Roman RJ. Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. J Smooth Muscle Res 2005;41:175-93.
4. Alkayed NJ, Goyagi T, Joh HD, Klaus J, Harder DR, Traystman RJ et al. Neuroprotection and P450 2C11 upregulation after experimental transient ischemic attack. Stroke 2002;33:1677-84.
5. Wu S, Chen W, Murphy E, Gabel S, Tomer KB, Foley J et al. Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem 1997;272:12551-9.
6. Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 2001;276:36059-62.
7. Zeldin DC, Moomaw CR, Jesse N, Tomer KB, Beetham J, Hammock BD et al. Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. Arch Biochem Biophys 1996;330:87-96.
8. Lasker JM, Chen WB, Wolf I, Bloswick BP, Wilson PD, Powell PK. Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. J Biol Chem 2000;275:4118-26.
9. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001;11:597-607.
10. King LM, Ma J, Srettabunjong S, Graves J, Bradbury JA, Li L et al. Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol Pharmacol 2002;61:840-52.
11. Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 2002;64:1579-89.
12. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996;6:341-9.
13. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994;4:39-42.
14. Stec DE, Roman RJ, Flasch A, Rieder MJ. Functional polymorphism in human CYP4F2 decreases 20-HETE production. Physiol Genomics 2007;30:74-81.
15. Gainer JV, Bellamine A, Dawson EP, Womble KE, Grant SW, Wang Y et al. Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation 2005;111:63-9.
16. Lee CR, Imig JD, Edin ML, Foley J, DeGraff LM, Bradbury JA et al. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J 2010;24:3770-81.
17. Sharma M, McCarthy ET, Reddy DS, Patel PK, Savin VJ, Medhora M et al. 8, 9-Epoxyeicosatrienoic acid protects the glomerular filtration barrier. Prostaglandins Other Lipid Mediat 2009;89:43-51.
18. Paller MS, Jacob HS. Cytochrome P-450 mediates tissue-damaging hydroxyl radical formation during reoxygenation of the kidney. Proc Natl Acad Sci USA 1994;91:7002-6.
19. Dolegowska B, Blogowski W, Domanski L. Is it possible to predict the early post-transplant allograft function using 20-HETE measurements? A preliminary report Transpl Int 2009;22:546-53.
20. Garcia M, Macias RM, Cubero JJ, Benitez J, Caravaca F, Gervasini G. ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients. Eur J Clin Pharmacol 2013;69:385-93.
21. Gervasini G, Garcia M, Macias RM, Benitez J, Caravaca F, Cubero JJ. CYP2C8*3 polymorphism and donor age are associated with allograft dysfunction in kidney transplant recipients treated with calcineurin inhibitors. J Clin Pharmacol 2013;53:427-34.
22. Gervasini G, Garcia M, Macias RM, Cubero JJ, Caravaca F, Benitez J. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. Transpl Int 2012;25:471-80.
23. Lundblad MS, Stark K, Eliasson E, Oliw E, Rane A. Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes. Biochem Biophys Res Commun 2005;327:1052-7.
24. Fava C, Ricci M, Melander O, Minuz P. Hypertension, cardiovascular risk and polymorphisms in genes controlling the cytochrome P450 pathway of arachidonic acid: a sex-specific relation? Prostaglandins Other Lipid Mediat 2012;98:75-85.
25. Fu Z, Ma Y, Xie X, Huang D, Yang H, Nakayama T et al. A novel polymorphism of the CYP4A11 gene is associated with coronary artery disease. Clin Appl Thromb Hemost 2013;19:60-5.
26. Liu PY, Li YH, Chao TH, Wu HL, Lin LJ, Tsai LM et al. Synergistic effect of cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset of premature myocardial infarction. Atherosclerosis 2007;195:199-206.
27. Spiecker M, Darius H, Hankeln T, Soufi M, Sattler AM, Schaefer JR et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 2004;110:2132-6.
28. Xiao B, Li X, Yan J, Yu X, Yang G, Xiao X et al. Overexpression of cytochrome P450 epoxygenases prevents development of hypertension in spontaneously hypertensive rats by enhancing atrial natriuretic peptide. J Pharmacol Exp Ther 2010;334:784-94.
29. Seubert J, Yang B, Bradbury JA, Graves J, Degraff LM, Gabel S et al. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res 2004;95:506-14.
30. Yang Q, Zhang RZ, Yim AP, He GW. Effect of 11, 12-epoxyeicosatrienoic acid as an additive to St. Thomas' cardioplegia and University of Wisconsin solutions on endothelium-derived hyperpolarizing factor-mediated function in coronary microarteries: influence of temperature and time. Ann Thorac Surg 2003;76:1623-30.
31. Deng Y, Edin ML, Theken KN, Schuck RN, Flake GP, Kannon MA et al. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. FASEB J 2011;25:703-13.
32. Zeldin DC, DuBois RN, Falck JR, Capdevila JH. Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform. Arch Biochem Biophys 1995;322:76-86.
33. Smith HE, Jones JP 3rd, Kalhorn TF, Farin FM, Stapleton PL, Davis CL et al. Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease. Pharmacogenet Genomics 2008;18:943-53.
34. Cheng J, Wu CC, Gotlinger KH, Zhang F, Falck JR, Narsimhaswamy D et al. 20-hydroxy-5, 8, 11, 14-eicosatetraenoic acid mediates endothelial dysfunction via IkappaB kinase-dependent endothelial nitric-oxide synthase uncoupling. J Pharmacol Exp Ther 2010;332:57-65.
35. Hermann M, Hellermann JP, Quitzau K, Hoffmann MM, Gasser T, Meinertz T et al. CYP4A11 polymorphism correlates with coronary endothelial dysfunction in patients with coronary artery disease-the ENCORE Trials. Atherosclerosis 2009;207:476-9.
36. Mayer B, Lieb W, Gotz A, Konig IR, Aherrahrou Z, Thiemig A et al. Association of the T8590C polymorphism of CYP4A11 with hypertension in the MONICA Augsburg echocardiographic substudy. Hypertension 2005;46:766-71.
37. Mayer B, Lieb W, Gotz A, Konig IR, Kauschen LF, Linsel-Nitschke P et al. Association of a functional polymorphism in the CYP4A11 gene with systolic blood pressure in survivors of myocardial infarction. J Hypertens 2006;24:1965-70.
38. Lee SH, Lee J, Cha R, Park MH, Ha JW, Kim S et al. Genetic variations in soluble epoxide hydrolase and graft function in kidney transplantation. Transplant Proc 2008;40:1353-6.
39. Picard N, Cresteil T, Premaud A, Marquet P. Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit 2004;26:600-8.
40. Woillard JB, Picard N, Thierry A, Touchard G, Marquet P. Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients. Pharmacogenet Genomics 2014;24:256-62.